Low dose colestipol in adolescents with familial hypercholesterolaemia.

S Tonstad, M Sivertsen, L Aksnes, L Ose

Medical Department A, National Hospital, Oslo, Norway.

The effects of orange flavoured colestipol granules, 10 g/day, in 37 boys and 29 girls aged 10-16 years with familial hypercholesterolaemia were examined first in an eight week double blind, placebo controlled protocol, then in open treatment for 44-52 weeks. All patients were on a low fat diet. Low density lipoprotein cholesterol levels were reduced by 19.5% by colestipol v 1.0% by placebo. Levels of serum folate, vitamin E, and carotenoids were reduced in the colestipol group, but not the vitamin E/cholesterol and carotenoid/cholesterol ratios or serum concentrations of vitamins A and D. After one year of colestipol, two thirds of the participants remained in the study, of whom half took > or = 80% of the prescribed dose. Those who took > or = 80% of the dose had a greater decrease in serum 25-hydroxyvitamin D levels than those who took < 80%. No adverse effects on weight gain or linear growth velocity were observed. Although low dose colestipol effectively reduces low density lipoprotein cholesterol levels, only a minority of adolescents adhered to the new formulation for one year. Folate and possibly vitamin D supplementation is recommended.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Haney, E. M., Huffman, L. H., Bougatsos, C., Freeman, M., Steiner, R. D., Nelson, H. D. (2007). Screening and Treatment for Lipid Disorders in Children and Adolescents: Systematic Evidence Review for the US Preventive Services Task Force. Pediatrics 120: e189-e214 [Abstract] [Full Text]  
• McCrindle, B. W., for the Writing Group, (2007). Summary of the American Heart Association's Scientific Statement on Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents. Arterioscler. Thromb. Vasc. Bio. 27: 982-985 [Full Text]  
• McCrindle, B. W., Urbina, E. M., Dennison, B. A., Jacobson, M. S., Steinberger, J., Rocchini, A. P., Hayman, L. L., Daniels, S. R. (2007). Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing. Circulation 115: 1948-1967 [Abstract] [Full Text]  
• Kavey, R.-E. W., Allada, V., Daniels, S. R., Hayman, L. L., McCrindle, B. W., Newburger, J. W., Parekh, R. S., Steinberger, J. (2006). Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation 114: 2710-2738 [Abstract] [Full Text]  
• Amundsen, A. L, Ose, L., Nenseter, M. S, Ntanios, F. Y (2002). Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am. J. Clin. Nutr. 76: 338-344 [Abstract] [Full Text]  
• Brier, K. L., Tornow, J. J., Ries, A. J., Weber, M. P., Downs, J. R. (1999). Forecasting Patient Outcomes in the Management of Hyperlipidemia. Arch Intern Med 159: 569-575 [Abstract] [Full Text]  
• Tonstad, S., Joakimsen, O., Stensland-Bugge, E., Leren, T. P., Ose, L., Russell, D., Bonaa, K. H. (1996). Risk Factors Related to Carotid Intima-Media Thickness and Plaque in Children With Familial Hypercholesterolemia and Control Subjects. Arterioscler. Thromb. Vasc. Bio. 16: 984-991 [Abstract] [Full Text]